| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $19,736,408 | 25 | 100 |
| Emany Sravan Kumar | Chief Financial Officer | 0 | $0 | 1 | $170,567 | $-170,567 |
| Cavanagh Bethany J | SVP, Finance and Treasurer | 0 | $0 | 4 | $392,570 | $-392,570 |
| Simon Amy | Chief Medical Officer | 0 | $0 | 3 | $606,677 | $-606,677 |
| Bellon Christine | Chief Legal Officer | 0 | $0 | 4 | $871,827 | $-871,827 |
| Ciaramella Giuseppe | President | 0 | $0 | 2 | $1.41M | $-1.41M |
| Evans John M. | CEO | 0 | $0 | 9 | $6.24M | $-6.24M |
| FMR LLC | See Remark 1 | 0 | $0 | 2 | $10.04M | $-10.04M |
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor …
Over the last 12 months, insiders at Beam Therapeutics Inc. have bought $0 and sold $19.74M worth of Beam Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Beam Therapeutics Inc. have bought $0 and sold $18.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-16 | Sale | Evans John M. | CEO | 25,000 0.0247% | $23.98 | $599,595 | +6.16% | |
| 2026-10-15 | Sale | Evans John M. | CEO | 25,000 0.0231% | $23.57 | $589,150 | +0.69% | |
| 2026-10-01 | Sale | Cavanagh Bethany J | SVP, Finance and Treasurer | 187 0.0002% | $24.41 | $4,565 | +1.84% | |
| 2026-07-27 | Sale | Simon Amy | Chief Medical Officer | 16,667 0.0166% | $25.74 | $429,037 | +2.85% | |
| 2026-06-30 | Sale | Evans John M. | CEO | 25,000 0.0243% | $34.31 | $857,685 | -23.28% | |
| 2026-06-30 | Sale | Simon Amy | Chief Medical Officer | 373 0.0004% | $34.73 | $12,954 | -23.28% | |
| 2026-06-29 | Sale | Evans John M. | CEO | 25,000 0.0247% | $35.49 | $887,352 | -24.66% | |
| 2026-06-26 | Sale | FMR LLC | See Remark 1 | 251,488 0.2476% | $35.26 | $8.87M | -24.13% | |
| 2026-06-25 | Sale | FMR LLC | See Remark 1 | 33,372 0.0336% | $35.12 | $1.17M | -21.93% | |
| 2026-04-01 | Sale | Evans John M. | CEO | 30,078 0.03% | $24.58 | $739,317 | +17.05% | |
| 2026-04-01 | Sale | Ciaramella Giuseppe | President | 11,810 0.0118% | $24.58 | $290,290 | +17.05% | |
| 2026-04-01 | Sale | Bellon Christine | Chief Legal Officer | 5,956 0.0059% | $24.58 | $146,398 | +17.05% | |
| 2026-04-01 | Sale | Simon Amy | Chief Medical Officer | 6,700 0.0067% | $24.58 | $164,686 | +17.05% | |
| 2026-04-01 | Sale | Cavanagh Bethany J | SVP, Finance and Treasurer | 3,242 0.0032% | $24.58 | $79,688 | +17.05% | |
| 2026-03-31 | Sale | Evans John M. | CEO | 25,000 0.0234% | $22.76 | $569,085 | +18.93% | |
| 2026-03-30 | Sale | Evans John M. | CEO | 25,000 0.0251% | $22.37 | $559,230 | +29.36% | |
| 2026-02-24 | Sale | Ciaramella Giuseppe | President | 35,000 0.0342% | $32.00 | $1.12M | -15.48% | |
| 2026-01-30 | Sale | Evans John M. | CEO | 25,000 0.0253% | $28.36 | $708,947 | -0.69% | |
| 2026-01-29 | Sale | Evans John M. | CEO | 25,000 0.0247% | $29.38 | $734,582 | -6.33% | |
| 2026-01-22 | Sale | Bellon Christine | Chief Legal Officer | 1,371 0.0013% | $34.00 | $46,614 | -19.76% |
| Increased Positions | 141 | +58.26% | 12M | +11.63% |
| Decreased Positions | 100 | -41.32% | 10M | -9.37% |
| New Positions | 61 | New | 5M | New |
| Sold Out Positions | 35 | Sold Out | 3M | Sold Out |
| Total Postitions | 283 | +16.94% | 109M | +2.26% |
| Fmr Llc | $317,344.00 | 11.58% | 11.69M | -1M | -9.79% | 2025-09-30 |
| Ark Investment Management Llc | $299,594.00 | 10.93% | 11.04M | +2M | +24.76% | 2025-09-30 |
| Farallon Capital Management Llc | $273,113.00 | 9.96% | 10.06M | +50,000 | +0.5% | 2025-09-30 |
| Vanguard Group Inc | $251,066.00 | 9.16% | 9.25M | -455,440 | -4.69% | 2025-09-30 |
| Blackrock, Inc. | $221,142.00 | 8.07% | 8.15M | +145,516 | +1.82% | 2025-09-30 |
| Sumitomo Mitsui Trust Group, Inc. | $131,106.00 | 4.78% | 4.83M | +101,294 | +2.14% | 2025-09-30 |
| Amova Asset Management Americas, Inc. | $131,106.00 | 4.78% | 4.83M | +103,939 | +2.2% | 2025-09-30 |
| Arch Venture Management, Llc | $123,219.00 | 4.5% | 4.54M | 0 | 0% | 2025-09-30 |
| State Street Corp | $108,795.00 | 3.97% | 4.01M | +370,392 | +10.18% | 2025-09-30 |
| Bellevue Group Ag | $78,415.00 | 2.86% | 2.89M | 0 | 0% | 2025-09-30 |